Oak Ridge Investments LLC Has $4.93 Million Position in C.R. Bard, Inc. (BCR)

Oak Ridge Investments LLC increased its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 37.7% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,595 shares of the medical instruments supplier’s stock after buying an additional 4,273 shares during the quarter. Oak Ridge Investments LLC’s holdings in C.R. Bard were worth $4,930,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in C.R. Bard by 70.4% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after buying an additional 190 shares in the last quarter. Parallel Advisors LLC lifted its position in C.R. Bard by 283.8% during the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 369 shares in the last quarter. ClariVest Asset Management LLC purchased a new position in C.R. Bard during the first quarter worth approximately $148,000. SRS Capital Advisors Inc. lifted its position in C.R. Bard by 0.7% during the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 4 shares in the last quarter. Finally, Stock Yards Bank & Trust Co. purchased a new position in C.R. Bard during the second quarter worth approximately $207,000. Hedge funds and other institutional investors own 79.34% of the company’s stock.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://sportsperspectives.com/2017/09/12/oak-ridge-investments-llc-has-4-93-million-position-in-c-r-bard-inc-bcr.html.

Shares of C.R. Bard, Inc. (BCR) opened at 323.39 on Tuesday. The firm has a 50-day moving average price of $320.16 and a 200-day moving average price of $295.78. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $324.23. The stock has a market cap of $23.50 billion, a P/E ratio of 42.46 and a beta of 0.60.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. During the same quarter in the prior year, the company posted $2.54 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, analysts anticipate that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.

A number of brokerages recently commented on BCR. Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. BidaskClub downgraded C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research downgraded C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, June 20th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $285.67.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply